Bright Minds Biosciences Inc
Research Bright Minds Biosciences Inc (DRUG) on Bullrun: market cap USD 533.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDRUG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 533.15M
- Financial periodQ3 2026
- Net income-CAD 2.40M
Valuation Snapshot
latest market cap is USD 533.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 12.23M | -CAD 8.69M | n/a | -1.78 | CAD 82.91M | CAD 125.78K | CAD 82.04M |
| FY2024 | CAD 0 | -CAD 2.80M | -CAD 1.85M | n/a | -0.65 | CAD 5.72M | CAD 118.96K | CAD 5.54M |
| FY2023 | CAD 0 | -CAD 7.37M | -CAD 7.02M | n/a | -1.98 | CAD 6.75M | CAD 73.55K | CAD 6.60M |
| FY2022 | CAD 0 | -CAD 14.96M | -CAD 13.59M | n/a | -6.06 | CAD 11.63M | CAD 139.91K | CAD 10.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 533.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 607.71M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 251.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.38M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 37.55M | n/a | n/a | n/a |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bright Minds Biosciences Inc's market cap?
Bright Minds Biosciences Inc's market capitalization is USD 533.15M.
What does Bright Minds Biosciences Inc do?
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.